STI-3258

STI-3258 is an anti-Trop2 antibody-drug conjugate (ADC) being developed by Sorrento Therapeutics for the treatment of relapsed or refractory solid tumors. It consists of a monoclonal antibody targeting the trophoblast cell-surface antigen 2 (Trop2), a glycoprotein frequently overexpressed in various epithelial cancers, conjugated to a cytotoxic payload. Upon binding to Trop2 on the surface of cancer cells, the ADC is internalized, and the payload is released to induce cell death. STI-3258 is currently being evaluated in a Phase 1b clinical trial (NCT05060276) to assess its safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors.